Coya Therapeutics, Inc.
COYA
$5.26
$0.040.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -99.97% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.97% | -- | -- | -- | -- |
| Cost of Revenue | 20.37% | 39.67% | 327.55% | 154.79% | -63.52% |
| Gross Profit | -144.06% | -39.67% | -6.83% | -144.48% | 199.55% |
| SG&A Expenses | -10.07% | 12.95% | 14.15% | 46.84% | 164.57% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.21% | 24.86% | 129.36% | 92.57% | 147.53% |
| Operating Income | -303.17% | -24.86% | -11.42% | -88.20% | 224.47% |
| Income Before Tax | -282.74% | -17.52% | 6.58% | -84.61% | 164.03% |
| Income Tax Expenses | -199.50% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -330.32% | -17.52% | 6.58% | -84.61% | 140.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -330.32% | -17.52% | 6.58% | -84.61% | 140.74% |
| EBIT | -303.17% | -24.86% | -11.42% | -88.20% | 224.47% |
| EBITDA | -302.14% | -24.91% | -11.45% | -88.41% | 225.42% |
| EPS Basic | -255.45% | 23.20% | 37.69% | -24.12% | 109.56% |
| Normalized Basic EPS | -212.38% | 23.21% | 29.74% | -23.54% | 118.85% |
| EPS Diluted | -255.45% | 23.20% | 37.69% | -24.12% | 109.56% |
| Normalized Diluted EPS | -212.38% | 23.21% | 29.74% | -23.54% | 118.85% |
| Average Basic Shares Outstanding | 48.23% | 53.01% | 49.93% | 48.72% | 326.04% |
| Average Diluted Shares Outstanding | 48.23% | 53.01% | 49.93% | 48.72% | 326.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |